Levothyroxine therapy reduces endocan and total cholesterol concentrations in patients with subclinical hypothyroidism
Biochemia Medica · 2025
DOI: 10.11613/bm.2025.010703 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemia Medica, 2025. Verfasst von Tihana Serdar Hiršl und 7 weiteren Autor:innen. Beteiligte Einrichtung: Synlab Croatia, Polyclinic for Medical Laboratory Diagnostics, Zagreb, Croatia. Hauptthemen laut MEDLINE: Proteoglycans, Thyroxine, Hypothyroidism, Neoplasm Proteins. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Subclinical hypothyroidism (SCH) is an independent risk factor for cardiovascular diseases due to endothelial dysfunction and atherosclerosis development. The aim of this study was to determine whether the levothyroxine therapy could impact the concentrations of endothelial dysfunction blood markers, namely endothelin-1 (ET-1), asymmetric dimethylarginine (ADMA) and endocan, in patients with a mild form of SCH (thyroid-stimulating hormone (TSH) ≤ 10 mIU/L). Materials and methods: In this case-control prospective study, SCH patients and healthy controls were recruited during their regular health examinations. Medical specialists prescribed levothyroxine to SCH patients if necessary. The endothelial dysfunction markers, as well as other biochemical markers, were measured in all subjects at baseline, and after 6 months of levothyroxine treatment following the euthyroidism.
Results
Our study showed higher ADMA (248.00 (168.78-540.20) vs. 166.30 (140.60-243.40) μg/L, P = 0.002), endocan (114.30 (63.45-194.65) vs. 67.26 (50.80-126.10) ng/L, P = 0.004), low-density lipoprotein cholesterol (LDL) (3.3 ± 0.6 vs. 3.7 ± 0.9 mmol/L, P = 0.043) and non-high-density lipoprotein cholesterol (non-HDL) (3.8 ± 0.7 vs. 4.2 ± 1.0 mmol/L, P = 0.020) concentrations in patients with a mild form of SCH in comparison with healthy subjects. In SCH patients, after 6 months of levothyroxine treatment following the euthyroidism, we observed a significant decrease in endocan (91.47 (61.88-200.03) vs. 97.90 (55.18-154.88) ng/L, P = 0.004), and total cholesterol concentrations (CHOL) (6.2 ± 1.0 vs. 5.8 ± 1.0 mmol/L, P = 0.039).
Conclusions
A mild form of SCH is associated with higher concentrations of endocan, ADMA, LDL and non-HDL. The potential benefits of levothyroxine therapy were shown through the significant decrease of endocan and CHOL concentrations in SCH patients, thus contributing the atherosclerosis prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Synlab Croatia, Polyclinic for Medical Laboratory Diagnostics, Zagreb, Croatia.
- Srebrnjak Children's Hospital, Zagreb, Croatia.
- Croatia Polyclinic, Zagreb, Croatia.
- Department of Clinical Chemistry, Sestre Milosrdnice University Hospital Centre, Zagreb, Croatia.
- Department of Oncology and Nuclear Medicine, Sestre Milosrdnice University Hospital Centre, Zagreb, Croatia.
- School of Medicine, University of Zagreb, Croatia.
Zitieren
APA
Serdar Hiršl, T., Đurić, K., Čeprnja, M., Zec, I., Kraljević Šmalcelj, M., Jukić, T., Bobetić-Vranić, T., & Somborac-Bačura, A. (2025). Levothyroxine therapy reduces endocan and total cholesterol concentrations in patients with subclinical hypothyroidism. Biochemia Medica. https://doi.org/10.11613/bm.2025.010703
Vancouver
Serdar Hiršl T, Đurić K, Čeprnja M, Zec I, Kraljević Šmalcelj M, Jukić T, et al. Levothyroxine therapy reduces endocan and total cholesterol concentrations in patients with subclinical hypothyroidism. Biochemia Medica. 2025. doi:10.11613/bm.2025.010703
BibTeX
@article{SerdarHirl2025,
author = {Serdar Hiršl, Tihana and Đurić, Koraljka and Čeprnja, Marina and Zec, Ivana and Kraljević Šmalcelj, Marijana and Jukić, Tomislav and Bobetić-Vranić, Tanja and Somborac-Bačura, Anita},
title = {Levothyroxine therapy reduces endocan and total cholesterol concentrations in patients with subclinical hypothyroidism},
journal = {Biochemia Medica},
year = {2025},
doi = {10.11613/bm.2025.010703}
}
EUVIMED